CY1115178T1 - Βιοδεικτες καρκινου - Google Patents
Βιοδεικτες καρκινουInfo
- Publication number
- CY1115178T1 CY1115178T1 CY20141100091T CY141100091T CY1115178T1 CY 1115178 T1 CY1115178 T1 CY 1115178T1 CY 20141100091 T CY20141100091 T CY 20141100091T CY 141100091 T CY141100091 T CY 141100091T CY 1115178 T1 CY1115178 T1 CY 1115178T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- biomarker
- industries
- detection
- peptide
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000090 biomarker Substances 0.000 abstract 3
- 206010060862 Prostate cancer Diseases 0.000 abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 2
- 238000001514 detection method Methods 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101100285412 Gallus gallus EN2 gene Proteins 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 108091023040 Transcription factor Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0625321.5A GB0625321D0 (en) | 2006-12-19 | 2006-12-19 | Cancer biomarker |
| GBGB0719792.4A GB0719792D0 (en) | 2006-12-19 | 2007-10-10 | Cancer biomarkers |
| EP07848631.3A EP2115472B1 (en) | 2006-12-19 | 2007-12-19 | Cancer biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115178T1 true CY1115178T1 (el) | 2016-12-14 |
Family
ID=39265269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100091T CY1115178T1 (el) | 2006-12-19 | 2014-02-05 | Βιοδεικτες καρκινου |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8460882B2 (OSRAM) |
| EP (1) | EP2115472B1 (OSRAM) |
| JP (1) | JP5683108B2 (OSRAM) |
| CN (1) | CN101675341B (OSRAM) |
| AU (1) | AU2007335999B2 (OSRAM) |
| BR (1) | BRPI0720371B8 (OSRAM) |
| CA (1) | CA2671939C (OSRAM) |
| CY (1) | CY1115178T1 (OSRAM) |
| DK (1) | DK2115472T3 (OSRAM) |
| ES (1) | ES2445185T3 (OSRAM) |
| GB (2) | GB0625321D0 (OSRAM) |
| IL (1) | IL199241A (OSRAM) |
| MX (1) | MX2009006378A (OSRAM) |
| NZ (1) | NZ577548A (OSRAM) |
| PL (1) | PL2115472T3 (OSRAM) |
| PT (1) | PT2115472E (OSRAM) |
| RU (1) | RU2460075C2 (OSRAM) |
| SI (1) | SI2115472T1 (OSRAM) |
| WO (1) | WO2008075056A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461126B2 (en) | 2005-10-14 | 2013-06-11 | Phigenix, Inc. | Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions |
| DE102006047617B4 (de) | 2006-10-09 | 2008-11-27 | Clariant International Limited | Verfahren zur Herstellung basischer (Meth)acrylamide |
| DE102008017216B4 (de) | 2008-04-04 | 2013-08-14 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden |
| GB0823445D0 (en) * | 2008-12-23 | 2009-01-28 | Univ Surrey | Biomarker |
| DE102009031059A1 (de) | 2009-06-30 | 2011-01-05 | Clariant International Ltd. | Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen |
| GB0912190D0 (en) * | 2009-07-13 | 2009-08-26 | Univ Surrey | Biomarker |
| JP2012532621A (ja) * | 2009-07-13 | 2012-12-20 | ザ ユニバーシティ オブ サリー | 治療ペプチド、ポリペプチド及び核酸配列 |
| GB0912175D0 (en) * | 2009-07-13 | 2009-08-26 | Univ Surrey | Biomarker |
| DE102009042523B4 (de) | 2009-09-22 | 2012-02-16 | Clariant International Ltd. | Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen |
| DE102009042522A1 (de) | 2009-09-22 | 2011-04-07 | Clariant International Ltd. | Kontinuierliches Umesterungsverfahren |
| GB0921329D0 (en) * | 2009-12-04 | 2010-01-20 | Univ Surrey | Biomarker |
| DE102010056565A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere |
| US20140106363A1 (en) * | 2011-05-12 | 2014-04-17 | Noviogendix Research B.V. | Molecular markers in prostate cancer |
| WO2012152800A1 (en) * | 2011-05-12 | 2012-11-15 | Noviogendix Research B.V. | Molecular markers in prostate cancer |
| CN103797120B (zh) * | 2011-09-16 | 2017-04-12 | 上海长海医院 | 前列腺癌的生物学标志物、治疗靶点及其用途 |
| JP5990274B2 (ja) * | 2011-12-05 | 2016-09-07 | ファイジェニクス インコーポレイテッド | 前立腺病態の処置のためのｅｎ２、ｐａｘ２、および／またはｄｅｆｂ１の標的化 |
| WO2014005138A1 (en) * | 2012-06-29 | 2014-01-03 | Kerschensteiner Daniel A | Colorimetric gelatinase assay |
| WO2014025961A1 (en) * | 2012-08-10 | 2014-02-13 | Analiza, Inc. | Methods and devices for analyzing species to determine diseases |
| WO2014179959A1 (en) * | 2013-05-09 | 2014-11-13 | The Procter & Gamble Company | Method and system for assessing health condition |
| WO2016102560A1 (en) * | 2014-12-23 | 2016-06-30 | The University Of Surrey | Glycosylated biomarker |
| KR101698654B1 (ko) | 2014-12-24 | 2017-01-20 | 포항공과대학교 산학협력단 | En2에 특이적으로 결합하는 dna 압타머 및 이의 용도 |
| US11827938B2 (en) * | 2015-05-29 | 2023-11-28 | Koninklijke Philips N.V. | Methods of prostate cancer prognosis |
| EP3352777B1 (en) * | 2015-09-23 | 2021-09-15 | Centre National De La Recherche Scientifique | Engrailed for use in the treatment of dna-damage in a patient suffering from parkinson disease |
| CN106282347A (zh) * | 2016-08-17 | 2017-01-04 | 中南大学 | HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用 |
| EP3564365B1 (en) | 2016-12-28 | 2023-01-25 | Guangzhou Institutes Of Biomedicine And Health Chinese Academy Of Sciences | Transdifferentation of b lymphoid cells into t cells |
| KR101777085B1 (ko) * | 2017-02-23 | 2017-09-11 | 주식회사 성균바이오텍 | En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물 |
| KR101777254B1 (ko) | 2017-07-14 | 2017-09-13 | 주식회사 무진메디 | En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 |
| KR101777259B1 (ko) | 2017-07-14 | 2017-09-13 | 주식회사 무진메디 | En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 |
| CN107727729A (zh) * | 2017-11-22 | 2018-02-23 | 南宁科城汇信息科技有限公司 | 一种oa候选标志物诊断模型的建立方法 |
| CN107894507A (zh) * | 2017-11-22 | 2018-04-10 | 南宁科城汇信息科技有限公司 | 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法 |
| KR101923199B1 (ko) | 2018-04-25 | 2018-11-28 | 주식회사 무진메디 | 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물 |
| CN111363817B (zh) * | 2018-12-26 | 2024-02-02 | 广州康立明生物科技股份有限公司 | 基于hoxd12基因的肺癌诊断剂及试剂盒 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0996725A1 (en) * | 1997-06-27 | 2000-05-03 | Human Genome Sciences, Inc. | Human nk-3 related prostate specific gene-1 |
| RU2234942C2 (ru) * | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| JP2002527758A (ja) * | 1998-10-19 | 2002-08-27 | ダイアデクスアス・インコーポレーテッド | 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法 |
| WO2001092879A1 (en) | 2000-05-30 | 2001-12-06 | Danmarks Miljø Undersøgelser | An assay method and kit for testing biological material for exposure to stress using biomarkers |
| JP2004501666A (ja) * | 2000-06-30 | 2004-01-22 | エピゲノミクス アーゲー | 薬理ゲノミクスのメチル化状態分析のための方法及び核酸 |
| WO2002022884A2 (en) * | 2000-09-12 | 2002-03-21 | Transgenetics Incorporated | Microarrayed organization of transcription factor target genes |
| AU2002249834B2 (en) | 2000-12-24 | 2008-05-22 | Iser Lubocki | A method for detecting biomarkers |
| US20040063216A1 (en) | 2000-12-24 | 2004-04-01 | Iser Lubocki | Method for detecting biomarkers |
| JP2004529630A (ja) * | 2001-03-01 | 2004-09-30 | エピゲノミクス アーゲー | 診断および治療目的の遺伝子パネルを遺伝子の発現およびメチル化状態に基づいて開発する方法 |
| US6949342B2 (en) * | 2001-12-21 | 2005-09-27 | Whitehead Institute For Biomedical Research | Prostate cancer diagnosis and outcome prediction by expression analysis |
| CA2469089A1 (en) * | 2003-07-08 | 2005-01-08 | Institut De Recherches Cliniques De Montreal | En-2 gene, disgnostic and therapeutic uses thereof |
| US20060014301A1 (en) | 2004-07-13 | 2006-01-19 | Power3 Medical Products, Inc. | Antibody-based system for detection of differential protein expression patterns |
| EP2284279A1 (en) * | 2004-12-02 | 2011-02-16 | Epigenomics AG | Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders |
| US9416422B2 (en) | 2005-02-18 | 2016-08-16 | Sloan-Kettering Institute For Cancer Research | Methods for detecting minimum residual disease |
-
2006
- 2006-12-19 GB GBGB0625321.5A patent/GB0625321D0/en not_active Ceased
-
2007
- 2007-10-10 GB GBGB0719792.4A patent/GB0719792D0/en not_active Ceased
- 2007-12-19 PT PT78486313T patent/PT2115472E/pt unknown
- 2007-12-19 CN CN200780051417.9A patent/CN101675341B/zh not_active Expired - Fee Related
- 2007-12-19 AU AU2007335999A patent/AU2007335999B2/en not_active Ceased
- 2007-12-19 CA CA2671939A patent/CA2671939C/en active Active
- 2007-12-19 WO PCT/GB2007/004902 patent/WO2008075056A1/en not_active Ceased
- 2007-12-19 DK DK07848631.3T patent/DK2115472T3/da active
- 2007-12-19 MX MX2009006378A patent/MX2009006378A/es active IP Right Grant
- 2007-12-19 EP EP07848631.3A patent/EP2115472B1/en not_active Not-in-force
- 2007-12-19 NZ NZ577548A patent/NZ577548A/en not_active IP Right Cessation
- 2007-12-19 RU RU2009127774/15A patent/RU2460075C2/ru not_active IP Right Cessation
- 2007-12-19 SI SI200731399T patent/SI2115472T1/sl unknown
- 2007-12-19 PL PL07848631T patent/PL2115472T3/pl unknown
- 2007-12-19 US US12/518,708 patent/US8460882B2/en active Active
- 2007-12-19 BR BRPI0720371A patent/BRPI0720371B8/pt not_active IP Right Cessation
- 2007-12-19 JP JP2009542216A patent/JP5683108B2/ja not_active Expired - Fee Related
- 2007-12-19 ES ES07848631.3T patent/ES2445185T3/es active Active
-
2009
- 2009-06-08 IL IL199241A patent/IL199241A/en active IP Right Grant
-
2014
- 2014-02-05 CY CY20141100091T patent/CY1115178T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2671939C (en) | 2017-10-03 |
| AU2007335999A1 (en) | 2008-06-26 |
| RU2460075C2 (ru) | 2012-08-27 |
| PT2115472E (pt) | 2014-02-14 |
| CN101675341B (zh) | 2017-08-08 |
| RU2009127774A (ru) | 2011-01-27 |
| ES2445185T3 (es) | 2014-02-28 |
| PL2115472T3 (pl) | 2014-05-30 |
| DK2115472T3 (da) | 2014-02-10 |
| US20100093558A1 (en) | 2010-04-15 |
| BRPI0720371A2 (pt) | 2013-12-31 |
| GB0719792D0 (en) | 2007-11-21 |
| WO2008075056A1 (en) | 2008-06-26 |
| IL199241A (en) | 2014-03-31 |
| MX2009006378A (es) | 2009-08-24 |
| BRPI0720371B8 (pt) | 2021-07-27 |
| CN101675341A (zh) | 2010-03-17 |
| CA2671939A1 (en) | 2008-06-26 |
| US8460882B2 (en) | 2013-06-11 |
| EP2115472B1 (en) | 2013-11-06 |
| GB0625321D0 (en) | 2007-01-24 |
| EP2115472A1 (en) | 2009-11-11 |
| AU2007335999B2 (en) | 2013-09-05 |
| NZ577548A (en) | 2012-03-30 |
| JP2010513901A (ja) | 2010-04-30 |
| JP5683108B2 (ja) | 2015-03-11 |
| SI2115472T1 (sl) | 2014-05-30 |
| BRPI0720371B1 (pt) | 2019-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115178T1 (el) | Βιοδεικτες καρκινου | |
| CY1119956T1 (el) | Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου | |
| CY1120913T1 (el) | Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους | |
| CY1111676T1 (el) | Μεθοδος για την θεραπεια του καρκινου με αντισταση στην γεφιτινιβη | |
| CY1119738T1 (el) | Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων | |
| CY1120434T1 (el) | Πρωτεϊνες προσδεσης il-1 | |
| IL285316A (en) | Detecting cancer, cancer tissue of origin, and/or a cancer cell type | |
| CY1121101T1 (el) | Μεθοδοι και στερεα υποστρωματα για παρασκευη δειγματος χρησιμοποιωντας τρανσποσωματα | |
| WO2008128169A8 (en) | Sparc and methods of use thereof | |
| CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
| CY1120208T1 (el) | Νεροτσουληθρα | |
| EP4242329A3 (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
| CR11504A (es) | Deteccion mejorada de la expresion de mage-a | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| NO20084546L (no) | Diagnostikk og behandlinger for tumorer | |
| CY1119112T1 (el) | K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος | |
| CY1118933T1 (el) | Anti-cxcr1 συνθεσεις και μεθοδοι | |
| CY1115700T1 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης | |
| DK2211180T3 (da) | Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer | |
| ECSP13012784A (es) | Anticuerpos anti-mesotelina e inmunoconjugados | |
| ECSP099523A (es) | Antagonistas específicos de VEGF para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadíos tempranos | |
| CY1116289T1 (el) | Θεραπευτικη αγωγη καρκινου του προστατη σε μεταστατικο σταδιο με δεγαρελιξη | |
| WO2008097908A3 (en) | Methods of diagnosing and prognosing lung cancer | |
| UY31105A1 (es) | Predicción pronóstica del melanoma | |
| CY1118244T1 (el) | Αντισωματα κατα της il-25 |